Z01 BC 010580 (Z01) | |||
---|---|---|---|
Title | Phase II Trial of PEG-Intron in Children with Diffuse Pontine Gliomas | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Warren, Katherine | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $34,098 | Project Dates | 10/01/2004 - N/A |
Fiscal Year | 2007 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Childhood Cancers (70.0%) Interferon (50.0%) Neurosciences Research (100.0%) |
Brain (100.0%) Nervous System (100.0%) |
||
Research Type | |||
Technology and/or Marker Testing in a Clinical Setting Systemic Therapies - Clinical Applications |
|||
Abstract | |||
In this study, pegylated interferon alfa-2b (PEG-Intron) is administerd subcutaneously once a week to pediatric patients with diffuse pontine gliomas who have completed radiation therapy. The endpoint of the trial is 2-year survival compared to historical controls. To date, 17 patients have been enrolled. All patients have tolerated the PEG-Introntherapy well, with no adverse events directly attributable to the study agent. The study is enrolling 24 patients and taking an early look for efficacy. Two of our patients to date have survived 2 years from diagnosis. The study is ongoing. |